TY - JOUR
T1 - Rifampin, rifapentine, and rifabutin are active against intracellular periprosthetic joint infection-associated staphylococcus epidermidis
AU - Fisher, Cody
AU - Patel, Robin
N1 - Publisher Copyright:
Copyright © 2021 American Society for Microbiology. All Rights Reserved.
PY - 2021/2
Y1 - 2021/2
N2 - Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a $2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis. These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.
AB - Staphylococcus epidermidis is a major cause of periprosthetic joint infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a $2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis. These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.
KW - Intracellular
KW - Periprosthetic joint infection
KW - Rifamycin
KW - Staphylococcus epidermidis
UR - http://www.scopus.com/inward/record.url?scp=85099978431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099978431&partnerID=8YFLogxK
U2 - 10.1128/AAC.01275-20
DO - 10.1128/AAC.01275-20
M3 - Article
C2 - 33199387
AN - SCOPUS:85099978431
SN - 0066-4804
VL - 65
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
IS - 2
M1 - e01275-20
ER -